BR0307206A - Agentes de formação de imagem direcionados por integrina - Google Patents
Agentes de formação de imagem direcionados por integrinaInfo
- Publication number
- BR0307206A BR0307206A BR0307206-1A BR0307206A BR0307206A BR 0307206 A BR0307206 A BR 0307206A BR 0307206 A BR0307206 A BR 0307206A BR 0307206 A BR0307206 A BR 0307206A
- Authority
- BR
- Brazil
- Prior art keywords
- integrin
- nanoparticles
- imaging agents
- agents
- directed imaging
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired - Fee Related
Links
- 239000012216 imaging agent Substances 0.000 title abstract 2
- 239000002105 nanoparticle Substances 0.000 abstract 3
- 239000013543 active substance Substances 0.000 abstract 1
- 238000009835 boiling Methods 0.000 abstract 1
- 239000003795 chemical substances by application Substances 0.000 abstract 1
- 239000011248 coating agent Substances 0.000 abstract 1
- 238000000576 coating method Methods 0.000 abstract 1
- 239000000839 emulsion Substances 0.000 abstract 1
- 210000002889 endothelial cell Anatomy 0.000 abstract 1
- 102000006495 integrins Human genes 0.000 abstract 1
- 108010044426 integrins Proteins 0.000 abstract 1
- 239000003446 ligand Substances 0.000 abstract 1
- 150000002632 lipids Chemical class 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 239000002245 particle Substances 0.000 abstract 1
- 239000004094 surface-active agent Substances 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K51/00—Preparations containing radioactive substances for use in therapy or testing in vivo
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/22—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations
- A61K49/222—Echographic preparations; Ultrasound imaging preparations ; Optoacoustic imaging preparations characterised by a special physical form, e.g. emulsions, liposomes
- A61K49/223—Microbubbles, hollow microspheres, free gas bubbles, gas microspheres
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/69—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit
- A61K47/6905—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion
- A61K47/6907—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the conjugate being characterised by physical or galenical forms, e.g. emulsion, particle, inclusion complex, stent or kit the form being a colloid or an emulsion the form being a microemulsion, nanoemulsion or micelle
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/0002—General or multifunctional contrast agents, e.g. chelated agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/04—X-ray contrast preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K49/00—Preparations for testing in vivo
- A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
- A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
- A61K49/1818—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles
- A61K49/1821—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles
- A61K49/1824—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles
- A61K49/1827—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle
- A61K49/1833—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes particles, e.g. uncoated or non-functionalised microparticles or nanoparticles coated or functionalised microparticles or nanoparticles coated or functionalised nanoparticles having a (super)(para)magnetic core, being a solid MRI-active material, e.g. magnetite, or composed of a plurality of MRI-active, organic agents, e.g. Gd-chelates, or nuclei, e.g. Eu3+, encapsulated or entrapped in the core of the coated or functionalised nanoparticle having a (super)(para)magnetic core coated or functionalised with a small organic molecule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- B—PERFORMING OPERATIONS; TRANSPORTING
- B82—NANOTECHNOLOGY
- B82Y—SPECIFIC USES OR APPLICATIONS OF NANOSTRUCTURES; MEASUREMENT OR ANALYSIS OF NANOSTRUCTURES; MANUFACTURE OR TREATMENT OF NANOSTRUCTURES
- B82Y5/00—Nanobiotechnology or nanomedicine, e.g. protein engineering or drug delivery
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Nanotechnology (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Radiology & Medical Imaging (AREA)
- Physics & Mathematics (AREA)
- Acoustics & Sound (AREA)
- Dispersion Chemistry (AREA)
- Biophysics (AREA)
- Biotechnology (AREA)
- General Engineering & Computer Science (AREA)
- Medical Informatics (AREA)
- Molecular Biology (AREA)
- Crystallography & Structural Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Optics & Photonics (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicinal Preparation (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
Abstract
"AGENTES DE FORMAçãO DE IMAGEM DIRECIONADOS POR INTEGRINA". Emulsões, preferencialmente de nanopartículas formadas a partir de substâncias perfluoroquímicas líquidas com alto ponto de ebulição, as referidas partículas revestidas com um revestimento de lipídio/tensoativo são feitas especificamente para regiões de células endoteliais, ativadas pela ligação das referidas nanopartículas a um ligando específico para integrina QvP3 que não seja um anticorpo. As nanopartículas podem ainda incluir agentes biologicamente ativos, radionuclídeos ou outros agentes de formação de imagem.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US35139002P | 2002-01-24 | 2002-01-24 | |
PCT/US2003/002380 WO2003062198A1 (en) | 2002-01-24 | 2003-01-24 | Integrin targeted imaging agents |
Publications (1)
Publication Number | Publication Date |
---|---|
BR0307206A true BR0307206A (pt) | 2004-12-21 |
Family
ID=27613494
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BR0307206-1A Expired - Fee Related BR0307206A (pt) | 2002-01-24 | 2003-01-24 | Agentes de formação de imagem direcionados por integrina |
Country Status (14)
Country | Link |
---|---|
US (3) | US7255875B2 (pt) |
EP (2) | EP1572639A4 (pt) |
JP (2) | JP4731117B2 (pt) |
KR (1) | KR100978126B1 (pt) |
CN (2) | CN101249269A (pt) |
AU (2) | AU2003209392B2 (pt) |
BR (1) | BR0307206A (pt) |
CA (1) | CA2474386C (pt) |
CO (1) | CO5601001A2 (pt) |
MX (1) | MXPA04007188A (pt) |
NZ (1) | NZ534500A (pt) |
TR (1) | TR200401834T2 (pt) |
WO (1) | WO2003062198A1 (pt) |
ZA (1) | ZA200406686B (pt) |
Families Citing this family (56)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20010003580A1 (en) | 1998-01-14 | 2001-06-14 | Poh K. Hui | Preparation of a lipid blend and a phospholipid suspension containing the lipid blend |
US7220401B2 (en) * | 1999-09-24 | 2007-05-22 | Barnes-Jewish Hospital | Blood clot-targeted nanoparticles |
US20080247943A1 (en) * | 1999-09-24 | 2008-10-09 | Gregory Lanza | Blood Clot-Targeted Nanoparticles |
US7951061B2 (en) * | 2001-07-25 | 2011-05-31 | Allan Foreman | Devices for targeted delivery of thermotherapy, and methods related thereto |
US7731648B2 (en) * | 2001-07-25 | 2010-06-08 | Aduro Biotech | Magnetic nanoscale particle compositions, and therapeutic methods related thereto |
EP1572639A4 (en) * | 2002-01-24 | 2006-08-09 | Barnes Jewish Hospital | IMAGING AGENTS TARGETING INTEGRINS |
US6869591B2 (en) * | 2002-03-26 | 2005-03-22 | Barnes-Jewish Hospital | Paramagnetic particles that provide improved relaxivity |
US20050079131A1 (en) * | 2003-08-08 | 2005-04-14 | Lanza Gregory M. | Emulsion particles for imaging and therapy and methods of use thereof |
JP2007517874A (ja) * | 2004-01-16 | 2007-07-05 | バーンズ−ジューイッシュ ホスピタル | 標的化アテローム性動脈硬化症治療法 |
JP2007526322A (ja) * | 2004-03-02 | 2007-09-13 | マサチューセッツ インスティテュート オブ テクノロジー | ナノセル薬物送達系 |
US20070053845A1 (en) * | 2004-03-02 | 2007-03-08 | Shiladitya Sengupta | Nanocell drug delivery system |
EP1768558A4 (en) * | 2004-06-09 | 2009-11-25 | Kereos Inc | LIPOPHILES DERIVATIVES OF CHELATE MONOAMIDES |
US20060047025A1 (en) * | 2004-06-29 | 2006-03-02 | Matthew Piazza | Viscous materials and method for producing |
WO2006096499A2 (en) * | 2005-03-04 | 2006-09-14 | Washington University | Mr coronary angiography with a fluorinated nanoparticle contrast agent at 1.5 t |
WO2006099445A2 (en) * | 2005-03-14 | 2006-09-21 | Massachusetts Institute Of Technology | Nanocells for diagnosis and treatment of diseases and disorders |
FR2883562B1 (fr) | 2005-03-24 | 2009-02-27 | Guerbet Sa | Chelates lipophiles et leur utilisation en imagerie |
CA2602385A1 (en) * | 2005-03-29 | 2006-10-05 | The Research Foundation Of State University Of New York | Hybrid inorganic nanoparticles, methods of using and methods of making |
CN101166987B (zh) * | 2005-04-26 | 2011-01-12 | 皇家飞利浦电子股份有限公司 | 在mri中使用cest造影剂的方法 |
US8306603B2 (en) * | 2005-04-26 | 2012-11-06 | Koninklijke Philips Electronics N.V. | MRI involving contrast agent with time modulated contrast enhancement |
JP2007079857A (ja) * | 2005-09-13 | 2007-03-29 | Canon Inc | サーバー装置、クライアント装置及びそれらの制御方法、コンピュータプログラム、記憶媒体 |
ES2627998T3 (es) | 2005-11-16 | 2017-08-01 | Exchange Imaging Technologies Gmbh | Nanopartículas fluorescentes |
EP2308513A3 (de) * | 2005-11-16 | 2011-11-23 | Signalomics GmbH | Fluoreszenz-Nanopartikel |
WO2007064800A2 (en) * | 2005-12-02 | 2007-06-07 | Barnes-Jewish Hospital | Methods to ameliorate and image angioplasty-induced vascular injury |
US20090317475A1 (en) * | 2006-01-03 | 2009-12-24 | Beardsley Robert A | Combination antitumor therapies |
US20070232909A1 (en) * | 2006-03-28 | 2007-10-04 | Washington University | Ultrasonic Characterization of Internal Body Conditions Using Information Theoretic Signal Receivers |
WO2007115115A2 (en) | 2006-03-29 | 2007-10-11 | Kereos, Inc. | Targeted mr imaging agents |
JP2009535126A (ja) * | 2006-04-27 | 2009-10-01 | バーンズ−ジューイッシュ ホスピタル | 標的組織の検出とイメージング |
AU2007329793B2 (en) * | 2006-10-24 | 2013-01-10 | Kereos, Inc. | Improved linkers for anchoring targeting ligands |
WO2008056623A1 (fr) * | 2006-11-09 | 2008-05-15 | Daiichi Sankyo Company, Limited | Composition pour l'introduction d'acide nucléique |
SG177996A1 (en) * | 2007-01-19 | 2012-02-28 | Triton Biosystems Inc | Thermotherapy susceptors and methods of using same |
US20080305046A1 (en) * | 2007-02-16 | 2008-12-11 | Ali Hafezi-Moghadam | Molecular imaging methods for diagnosis and evaluation of ocular and systemic diseases |
JP5249248B2 (ja) | 2007-03-05 | 2013-07-31 | ワシントン ユニバーシティー | 膜組み込みペプチドのためのナノ粒子輸送システム |
US8372427B2 (en) * | 2007-03-05 | 2013-02-12 | Abbott Cardiovascular Systems Inc. | Therapeutic composition with enhanced endothelium targeting |
FR2914303A1 (fr) | 2007-03-28 | 2008-10-03 | Guerbet Sa | Composes pour le diagnostic de l'apoptose. |
FR2914304B1 (fr) | 2007-03-28 | 2012-11-16 | Guerbet Sa | Composes pour le diagnostic de maladies liees a l'expression de vcam. |
WO2009151788A2 (en) * | 2008-04-22 | 2009-12-17 | The Washington University | Universal anchor peptide for nanoparticles |
US9125949B2 (en) * | 2008-12-30 | 2015-09-08 | University Of North Texas | Direct utilization of plasma proteins for the in vivo assembly of protein-drug/imaging agent conjugates, nanocarriers and coatings for biomaterials |
FR2942227B1 (fr) | 2009-02-13 | 2011-04-15 | Guerbet Sa | Utilisation de tampons pour la complexation de radionucleides |
JP2013507365A (ja) * | 2009-10-07 | 2013-03-04 | サンフォード−バーナム メディカル リサーチ インスティテュート | 血餅結合脂質化合物に関する方法および組成物 |
WO2011071778A1 (en) | 2009-12-07 | 2011-06-16 | Mayo Foundation For Medical Education And Research | Device for the delineation of cardiovascular or other anatomical structures |
FR2968562B1 (fr) | 2010-12-14 | 2013-01-11 | Guerbet Sa | Composes pour le diagnostic de maladies liees a l'expression de muc5ac |
FR2968999B1 (fr) | 2010-12-20 | 2013-01-04 | Guerbet Sa | Nanoemulsion de chelate pour irm |
JP2014510743A (ja) * | 2011-03-31 | 2014-05-01 | シェファー、コンスタンツェ | 核酸の非ウイルスの導入のためのパーフルオロ化化合物 |
KR20140037208A (ko) | 2011-06-21 | 2014-03-26 | 이뮤노젠 아이엔씨 | 펩타이드 링커를 갖는 신규한 메이탄시노이드 유도체 및 이의 접합체 |
FR2980365B1 (fr) | 2011-09-26 | 2016-02-12 | Guerbet Sa | Nanoemulsions, leur procede de preparation, et leur utilisation comme agent de contraste. |
FR2980364B1 (fr) | 2011-09-26 | 2018-08-31 | Guerbet | Nanoemulsions et leur utilisation comme agents de contraste |
FR3000688B1 (fr) * | 2013-01-08 | 2016-09-30 | Centre Nat De La Rech Scient - Cnrs - | Procede pour activer une reaction chimique, melange activable par ce procede et dispostiif pour la mise en oeuvre de ce procede |
FR3001154B1 (fr) | 2013-01-23 | 2015-06-26 | Guerbet Sa | Magneto-emulsion vectorisee |
WO2014186435A2 (en) | 2013-05-14 | 2014-11-20 | University Of Georgia Research Foundation, Inc. | Compositions and methods for reducing neointima formation |
ES2883837T3 (es) | 2014-05-02 | 2021-12-09 | The Res Institute At Nationwide Childrens Hospital | Composiciones y métodos para inmunomodulación de anti-LYST |
US10449269B2 (en) | 2016-08-29 | 2019-10-22 | Yale University | Particle conjugated prosthetic patches and methods of making and using thereof |
US11312685B2 (en) * | 2017-04-28 | 2022-04-26 | Texas Heart Institute | Targeting nanoparticles |
WO2019232362A1 (en) * | 2018-05-31 | 2019-12-05 | University Of South Florida | Nanoparticle delivery system for diseases associated with major basement membrane components of blood vessels accessible from blood stream |
WO2020007822A1 (en) | 2018-07-02 | 2020-01-09 | Conservatoire National Des Arts Et Metiers (Cnam) | Bismuth metallic (0) nanoparticles, process of manufacturing and uses thereof |
CN110433296A (zh) * | 2019-08-16 | 2019-11-12 | 哈尔滨医科大学 | 一种19f-mr/荧光多模式分子成像及载药的诊疗一体化纳米探针及制备方法和应用 |
CN117377495A (zh) * | 2021-06-09 | 2024-01-09 | 克林提克斯医药股份有限公司 | 非肽靶向治疗剂及其用途 |
Family Cites Families (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US613023A (en) | 1898-10-25 | Wire clothes-pin | ||
WO1987002893A1 (en) | 1985-11-18 | 1987-05-21 | Board Of Regents, The University Of Texas System | Polychelating agents for image and spectral enhancement (and spectral shift) |
US4927623A (en) | 1986-01-14 | 1990-05-22 | Alliance Pharmaceutical Corp. | Dissolution of gas in a fluorocarbon liquid |
US5077036A (en) | 1986-01-14 | 1991-12-31 | Alliance Pharmaceutical Corp. | Biocompatible stable fluorocarbon emulsions for contrast enhancement and oxygen transport comprising 40-125% wt./volume fluorocarbon combined with a phospholipid |
US5171755A (en) | 1988-04-29 | 1992-12-15 | Hemagen/Pfc | Emulsions of highly fluorinated organic compounds |
US5114703A (en) | 1989-05-30 | 1992-05-19 | Alliance Pharmaceutical Corp. | Percutaneous lymphography using particulate fluorocarbon emulsions |
US5087440A (en) | 1989-07-31 | 1992-02-11 | Salutar, Inc. | Heterocyclic derivatives of DTPA used for magnetic resonance imaging |
US5542935A (en) | 1989-12-22 | 1996-08-06 | Imarx Pharmaceutical Corp. | Therapeutic delivery systems related applications |
US5409688A (en) | 1991-09-17 | 1995-04-25 | Sonus Pharmaceuticals, Inc. | Gaseous ultrasound contrast media |
US5304325A (en) | 1991-11-13 | 1994-04-19 | Hemagen/Pfc | Emulsions containing alkyl- or alkylglycerophosphoryl choline surfactants and methods of use |
US5403575A (en) | 1991-12-12 | 1995-04-04 | Hemagen/Pfc | Highly fluorinated, chloro-substituted organic compound-containing emulsions and methods of using them |
WO1994014415A1 (en) * | 1992-12-24 | 1994-07-07 | Hemagen/Pfc | Fluorocarbon emulsions |
IL106578A (en) | 1993-08-03 | 2000-08-13 | Yissum Res Dev Co | Pharmaceutical compositions for drug targeting |
WO1995027705A1 (en) | 1994-04-08 | 1995-10-19 | Bracco International B.V. | Aromatic amide compounds and metal chelates thereof |
US5571498A (en) | 1994-06-02 | 1996-11-05 | Hemagen/Pfc | Emulsions of paramagnetic contrast agents for magnetic resonance imaging (MRI). |
US5614170A (en) | 1994-11-30 | 1997-03-25 | Hemagen/Pfc | Paramagnetic complexes of N-alkyl-N-hydroxylamides of organic acids and emulsions containing same for magnetic resonance imaging (MRI) |
US5520904A (en) * | 1995-01-27 | 1996-05-28 | Mallinckrodt Medical, Inc. | Calcium/oxyanion-containing particles with a polymerical alkoxy coating for use in medical diagnostic imaging |
DE69632401T2 (de) * | 1995-06-07 | 2005-05-19 | Imarx Pharmaceutical Corp., Tucson | Neue zielgerichtete mittel zur diagnostischen und therapeutischen verwendung |
US6521211B1 (en) | 1995-06-07 | 2003-02-18 | Bristol-Myers Squibb Medical Imaging, Inc. | Methods of imaging and treatment with targeted compositions |
US5780010A (en) * | 1995-06-08 | 1998-07-14 | Barnes-Jewish Hospital | Method of MRI using avidin-biotin conjugated emulsions as a site specific binding system |
US5958371A (en) | 1995-06-08 | 1999-09-28 | Barnes-Jewish Hospital | Site specific binding system, nuclear imaging compositions and methods |
US6821506B2 (en) * | 1995-06-08 | 2004-11-23 | Barnes-Jewish Hospital | Site specific binding system, imaging compositions and methods |
US5690907A (en) * | 1995-06-08 | 1997-11-25 | The Jewish Hospital Of St. Louis | Avidin-biotin conjugated emulsions as a site specific binding system |
AU5362998A (en) * | 1996-11-27 | 1998-06-22 | Du Pont Pharmaceuticals Company | Novel integrin receptor antagonists |
DK0973550T3 (da) | 1997-04-11 | 2003-02-10 | Searle & Co | Antagonistiske anti-AVB3-integrin-antistoffer |
WO1999026945A1 (en) | 1997-11-26 | 1999-06-03 | Du Pont Pharmaceuticals Company | 1,3,4-THIADIAZOLES AND 1,3,4-OXADIAZOLES AS αvβ3 ANTAGONISTS |
HUP0101468A2 (hu) | 1998-03-31 | 2001-08-28 | Du Pont Pharmaceuticals Company | Angiogenetikus rendellenességek leképzésére alkalmas szerek |
US6056939A (en) | 1998-08-28 | 2000-05-02 | Desreux; Jean F. | Self-assembling heteropolymetallic chelates as imaging agents and radiopharmaceuticals |
AU2371400A (en) | 1998-12-18 | 2000-07-03 | Du Pont Pharmaceuticals Company | Vitronectin receptor antagonist pharmaceuticals |
PT1140203E (pt) | 1998-12-18 | 2007-08-30 | Bristol Myers Squibb Pharma Co | Medicamentos antagonistas do receptor da vitronectina |
BR9917079A (pt) * | 1998-12-18 | 2001-10-30 | Du Pont Pharm Co | Compostos antagonistas de receptor devitronectina, kit, composição metalofarmacêuticade diagnóstico ou terapêutica, composição deagente de contraste para ultra-som, composiçãoradiofarmacêutica terapêutica, composiçãofarmacêutica de diagnóstico, método detratamento da artrite reumatóide, do cancêr e darestenose em um paciente, método de formação deimagem da angiogênese terapêutica, do câncer, denovos vasos sanguìneos, da arteriosclerose, darestenose, da isquemia e da lesão por reperfusãodo miocárdio em um paciente |
WO2001012217A1 (en) * | 1999-08-18 | 2001-02-22 | Altarex Corp. | Therapeutic antibody against muc-1 antigen and methods for their use |
MXPA02012750A (es) * | 2000-06-21 | 2004-07-30 | Bristol Myers Squibb Pharma Co | Compuestos farmaceuticos antagonistas del receptor de la vitronectina para su uso en terapia de combinacion. |
US6875419B2 (en) | 2000-11-20 | 2005-04-05 | Board Of Regents The University Of Texas System | Paramagnetic metal ion-based macrocyclic magnetization transfer contrast agents and method of use |
US7179449B2 (en) | 2001-01-30 | 2007-02-20 | Barnes-Jewish Hospital | Enhanced ultrasound detection with temperature-dependent contrast agents |
MXPA04001113A (es) * | 2001-08-08 | 2004-07-08 | Bristol Myers Squibb Pharma Co | Formacion de imagenes simultaneas de perfusion cardiaca y agente formador de imagenes dirigido al receptor de vitronectina. |
EP1572639A4 (en) * | 2002-01-24 | 2006-08-09 | Barnes Jewish Hospital | IMAGING AGENTS TARGETING INTEGRINS |
-
2003
- 2003-01-24 EP EP03707550A patent/EP1572639A4/en not_active Withdrawn
- 2003-01-24 EP EP10185536A patent/EP2269659A1/en not_active Withdrawn
- 2003-01-24 CN CNA2007101667648A patent/CN101249269A/zh active Pending
- 2003-01-24 TR TR2004/01834T patent/TR200401834T2/xx unknown
- 2003-01-24 KR KR1020047011515A patent/KR100978126B1/ko not_active IP Right Cessation
- 2003-01-24 AU AU2003209392A patent/AU2003209392B2/en not_active Ceased
- 2003-01-24 NZ NZ534500A patent/NZ534500A/en unknown
- 2003-01-24 WO PCT/US2003/002380 patent/WO2003062198A1/en active Application Filing
- 2003-01-24 CA CA2474386A patent/CA2474386C/en not_active Expired - Fee Related
- 2003-01-24 BR BR0307206-1A patent/BR0307206A/pt not_active Expired - Fee Related
- 2003-01-24 MX MXPA04007188A patent/MXPA04007188A/es unknown
- 2003-01-24 US US10/351,463 patent/US7255875B2/en not_active Expired - Fee Related
- 2003-01-24 JP JP2003562080A patent/JP4731117B2/ja not_active Expired - Fee Related
- 2003-01-24 CN CNB038068575A patent/CN100356984C/zh not_active Expired - Fee Related
-
2004
- 2004-08-19 CO CO04080978A patent/CO5601001A2/es not_active Application Discontinuation
- 2004-08-23 ZA ZA200406686A patent/ZA200406686B/en unknown
-
2005
- 2005-12-16 US US11/305,416 patent/US7344698B2/en not_active Expired - Fee Related
-
2008
- 2008-01-09 US US11/971,818 patent/US7566442B2/en not_active Expired - Fee Related
-
2009
- 2009-01-09 AU AU2009200095A patent/AU2009200095A1/en not_active Abandoned
-
2010
- 2010-07-30 JP JP2010171706A patent/JP5444154B2/ja not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
NZ534500A (en) | 2007-07-27 |
AU2003209392B2 (en) | 2008-10-09 |
US20040058951A1 (en) | 2004-03-25 |
CA2474386C (en) | 2011-07-05 |
CA2474386A1 (en) | 2003-07-31 |
WO2003062198A3 (en) | 2005-08-04 |
JP2010248248A (ja) | 2010-11-04 |
CN1738815A (zh) | 2006-02-22 |
US7566442B2 (en) | 2009-07-28 |
JP4731117B2 (ja) | 2011-07-20 |
MXPA04007188A (es) | 2005-10-18 |
TR200401834T2 (tr) | 2005-10-21 |
US20060147380A1 (en) | 2006-07-06 |
CO5601001A2 (es) | 2006-01-31 |
US7255875B2 (en) | 2007-08-14 |
JP2005525319A (ja) | 2005-08-25 |
EP2269659A1 (en) | 2011-01-05 |
CN101249269A (zh) | 2008-08-27 |
ZA200406686B (en) | 2005-09-19 |
EP1572639A1 (en) | 2005-09-14 |
US7344698B2 (en) | 2008-03-18 |
KR100978126B1 (ko) | 2010-08-26 |
EP1572639A4 (en) | 2006-08-09 |
WO2003062198A8 (en) | 2003-11-06 |
WO2003062198A1 (en) | 2003-07-31 |
KR20040090986A (ko) | 2004-10-27 |
JP5444154B2 (ja) | 2014-03-19 |
CN100356984C (zh) | 2007-12-26 |
US20080175792A1 (en) | 2008-07-24 |
AU2009200095A1 (en) | 2009-02-05 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BR0307206A (pt) | Agentes de formação de imagem direcionados por integrina | |
Kiss | Caveolae and the regulation of endocytosis | |
Levental et al. | Palmitoylation regulates raft affinity for the majority of integral raft proteins | |
Kliesch et al. | Membrane tension increases fusion efficiency of model membranes in the presence of SNAREs | |
Takahashi et al. | Tunneling nanotube formation is essential for the regulation of osteoclastogenesis | |
BRPI0812770A2 (pt) | Método in vitro para identificar uma pluralidade de moléculas antigênicas transportadas por eritrócitos de um indivíduo, e/ou identificar uma pluralidade de anticorpos contra moléculas antigênicas transportadas por eritrócitos, conjunto de reagentes para implementar o método de detecção . | |
AR047611A1 (es) | Formulaciones liquidas de anticuerpos anti-egfr altamente concentradas | |
WO2007051169A3 (en) | Use of b cell expansion agents in generating antibodies | |
EP1715391A3 (en) | Image forming method and image forming apparatus for forming an image on a transparent substrate | |
Fujimoto et al. | Colocalization of quantum dots by reactive molecules carried by motor proteins on polarized microtubule arrays | |
BRPI0210579B8 (pt) | anticorpo e composição farmacêutica | |
WO2007096535A3 (fr) | Procede de fabrication d'un reseau de capillaires d'une puce | |
WO2008019376A3 (en) | Compositions and methods using anti-cs1 antibodies to treat multiple myeloma | |
WO2006102200A3 (en) | Docetaxel immunoassay | |
WO2005010215A3 (en) | Methods for identifying tolerance modulatory compounds and uses therefor | |
BRPI0511802A (pt) | processo para criação de meios para uso em separadores de ar/óleo | |
Aldeek et al. | Patterned hydrophobic domains in the exopolymer matrix of Shewanella oneidensis MR-1 biofilms | |
Joseph et al. | Complimentary action of structured and unstructured domains of epsin supports clathrin-mediated endocytosis at high tension | |
TW200702938A (en) | Lithographic apparatus and device manufacturing method | |
Enomoto et al. | Cationic surfactants induce apoptosis in normal and cancer cells | |
TW200701258A (en) | Ionic material and application thereof | |
Kim et al. | New autonomous water-enabled self-healing coating material with antibacterial-agent-releasing properties | |
Kramer et al. | Cell‐surface matrix proteins and sialic acids in cell‐crystal adhesion; the effect of crystal binding on the viability of human CAKI‐1 renal epithelial cells | |
WO2008076916A3 (en) | Thallium-sensitive agents and methods of using the same | |
WO2004104726A3 (en) | Managing a non-qualified deferred compensation using hedging |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application fees: application dismissed [chapter 8.6 patent gazette] |
Free format text: REFERENTE AS 8A, 9A E 10A ANUIDADES. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2204 DE 02/04/2013. |